Figure 1 FS1 from FGFR mRNA Expression in Cholangiocarcinoma and Its Correlation with <i>FGFR2</i> Fusion Status and Immune Signatures

Figure 1 FS1 from FGFR mRNA Expression in Cholangiocarcinoma and Its Correlation with <i>FGFR2</i> Fusion Status and Immune Signatures

<p>Supplementary Figure 1</p>

Furkejuvvon:

Bibliográfalaš dieđut
Váldodahkki:	Vishwajith Sridharan (15047154) (author)
Eará dahkkit:	Azfar Neyaz (15047157) (author), Abhijit Chogule (15047160) (author), Islam Baiev (15047163) (author), Stephanie Reyes (15047166) (author), Emily G. Barr Fritcher (15047169) (author), Jochen K. Lennerz (15014703) (author), William Sukov (15047172) (author), Benjamin Kipp (15047175) (author), David T. Ting (15018716) (author), Vikram Deshpande (15047178) (author), Lipika Goyal (15047181) (author)
Almmustuhtton:	2025
Fáttát:	Cancer Therapeutic Research and Development Immuno-oncology Clinical Research and Trials Gastrointestinal Cancers Immunotherapy Checkpoint blockade Precision Medicine Translational Research
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!

Geahča maid

Figure S1 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
Dahkki: Evan C. Chen (15054014)
Almmustuhtton: (2025)

Figure S2 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
Dahkki: Evan C. Chen (15054014)
Almmustuhtton: (2025)

Figure S3 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
Dahkki: Evan C. Chen (15054014)
Almmustuhtton: (2025)

Figure S4 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
Dahkki: Evan C. Chen (15054014)
Almmustuhtton: (2025)

Figure S5 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
Dahkki: Evan C. Chen (15054014)
Almmustuhtton: (2025)

Figure S6 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
Dahkki: Evan C. Chen (15054014)
Almmustuhtton: (2025)

Supplementary Data from <i>N</i><sup>6</sup>-methyladenosine Modification of FZR1 mRNA Promotes Gemcitabine Resistance in Pancreatic Cancer
Dahkki: Jiachun Su (16990970)
Almmustuhtton: (2025)

Supplementary Figure S1 from Association of Antifolate Response Signature Status and Clinical Activity of Pemetrexed-Platinum Chemotherapy in Non–Small Cell Lung Cancer: The Piedmont Study
Dahkki: Joel R. Eisner (15132120)
Almmustuhtton: (2025)

Supplementary Figure S2 from Association of Antifolate Response Signature Status and Clinical Activity of Pemetrexed-Platinum Chemotherapy in Non–Small Cell Lung Cancer: The Piedmont Study
Dahkki: Joel R. Eisner (15132120)
Almmustuhtton: (2025)

Supplementary Table S2 from Association of Antifolate Response Signature Status and Clinical Activity of Pemetrexed-Platinum Chemotherapy in Non–Small Cell Lung Cancer: The Piedmont Study
Dahkki: Joel R. Eisner (15132120)
Almmustuhtton: (2025)

Figure 1 from <i>In Vivo</i> Modeling of Patient Genetic Heterogeneity Identifies New Ways to Target Cholangiocarcinoma
Dahkki: Nicholas T. Younger (14956251)
Almmustuhtton: (2025)

Figure 2 from <i>In Vivo</i> Modeling of Patient Genetic Heterogeneity Identifies New Ways to Target Cholangiocarcinoma
Dahkki: Nicholas T. Younger (14956251)
Almmustuhtton: (2025)

Figure 3 from <i>In Vivo</i> Modeling of Patient Genetic Heterogeneity Identifies New Ways to Target Cholangiocarcinoma
Dahkki: Nicholas T. Younger (14956251)
Almmustuhtton: (2025)

Figure 4 from <i>In Vivo</i> Modeling of Patient Genetic Heterogeneity Identifies New Ways to Target Cholangiocarcinoma
Dahkki: Nicholas T. Younger (14956251)
Almmustuhtton: (2025)

Genetic variation and mRNA expression of the <i>ELOVL6</i> and <i>CRTC2</i> genes in Kalmyk cattle
Dahkki: Nurlybay Kazhgaliyev (9904228)
Almmustuhtton: (2025)

APP deficiency did not affect the mRNA level of <i>Scn8a</i> in cerebellar PCs.
Dahkki: Miao-Jin Ji (22676552)
Almmustuhtton: (2025)

Figure 1 from Biological Misinterpretation of Transcriptional Signatures in Tumor Samples Can Unknowingly Undermine Mechanistic Understanding and Faithful Alignment with Preclinical Data
Dahkki: Natalie C. Fisher (15046025)
Almmustuhtton: (2025)

Figure 2 from Biological Misinterpretation of Transcriptional Signatures in Tumor Samples Can Unknowingly Undermine Mechanistic Understanding and Faithful Alignment with Preclinical Data
Dahkki: Natalie C. Fisher (15046025)
Almmustuhtton: (2025)

Figure 3 from Biological Misinterpretation of Transcriptional Signatures in Tumor Samples Can Unknowingly Undermine Mechanistic Understanding and Faithful Alignment with Preclinical Data
Dahkki: Natalie C. Fisher (15046025)
Almmustuhtton: (2025)

Figure 4 from Biological Misinterpretation of Transcriptional Signatures in Tumor Samples Can Unknowingly Undermine Mechanistic Understanding and Faithful Alignment with Preclinical Data
Dahkki: Natalie C. Fisher (15046025)
Almmustuhtton: (2025)

Figure 5 from Biological Misinterpretation of Transcriptional Signatures in Tumor Samples Can Unknowingly Undermine Mechanistic Understanding and Faithful Alignment with Preclinical Data
Dahkki: Natalie C. Fisher (15046025)
Almmustuhtton: (2025)

Figure 6 from Biological Misinterpretation of Transcriptional Signatures in Tumor Samples Can Unknowingly Undermine Mechanistic Understanding and Faithful Alignment with Preclinical Data
Dahkki: Natalie C. Fisher (15046025)
Almmustuhtton: (2025)

Supplementary Figure S1 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer
Dahkki: Carlotta Antoniotti (15352506)
Almmustuhtton: (2025)

Supplementary Figure S2 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer
Dahkki: Carlotta Antoniotti (15352506)
Almmustuhtton: (2025)

Supplementary Figure S3 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer
Dahkki: Carlotta Antoniotti (15352506)
Almmustuhtton: (2025)

Supplemental Data File S3 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
Dahkki: Katie E. Hebron (15046889)
Almmustuhtton: (2025)

Supplementary Data File S1 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
Dahkki: Katie E. Hebron (15046889)
Almmustuhtton: (2025)

Supplementary Data File S2 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
Dahkki: Katie E. Hebron (15046889)
Almmustuhtton: (2025)

Supplementary Data File S6 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
Dahkki: Katie E. Hebron (15046889)
Almmustuhtton: (2025)

Supplementary Data File S7 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
Dahkki: Katie E. Hebron (15046889)
Almmustuhtton: (2025)

Supplementary Data File S8 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
Dahkki: Katie E. Hebron (15046889)
Almmustuhtton: (2025)

Supplementary Data File S9 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
Dahkki: Katie E. Hebron (15046889)
Almmustuhtton: (2025)

Table S1 from Distinct Genetically Determined Origins of <i>Myd88</i>/<i>BCL2</i>-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies
Dahkki: Ruth Flümann (15123900)
Almmustuhtton: (2025)

Table S2 from Distinct Genetically Determined Origins of <i>Myd88</i>/<i>BCL2</i>-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies
Dahkki: Ruth Flümann (15123900)
Almmustuhtton: (2025)

Table S3 from Distinct Genetically Determined Origins of <i>Myd88</i>/<i>BCL2</i>-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies
Dahkki: Ruth Flümann (15123900)
Almmustuhtton: (2025)

Table S4 from Distinct Genetically Determined Origins of <i>Myd88</i>/<i>BCL2</i>-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies
Dahkki: Ruth Flümann (15123900)
Almmustuhtton: (2025)

Table S5 from Distinct Genetically Determined Origins of <i>Myd88</i>/<i>BCL2</i>-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies
Dahkki: Ruth Flümann (15123900)
Almmustuhtton: (2025)

Table S6 from Distinct Genetically Determined Origins of <i>Myd88</i>/<i>BCL2</i>-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies
Dahkki: Ruth Flümann (15123900)
Almmustuhtton: (2025)

Supplementary Figure S1 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
Dahkki: Chong Kin Liam (15331321)
Almmustuhtton: (2025)

Supplementary Figure S2 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
Dahkki: Chong Kin Liam (15331321)
Almmustuhtton: (2025)

Cannot write session to /tmp/vufind_sessions/sess_s94dle0v3h6tpddaocj83q3e0i